Press Releases

Edgemont Capital Partners advises PharmAnalysis Group, Inc. on its acquisition by United BioSource Corp.

acquired by
August 2004

MEDTAP® International, Inc. announced today that it has broadened its research and consultation services to include strategic reimbursement planning through the addition of PharmAnalysis Group, Inc., a provider of reimbursement planning for the pharmaceutical, biotechnology, medical device and diagnostics industries, as MEDTAP’s new Center for Pricing and Reimbursement. With this addition, MEDTAP, a global research organization specializing in outcomes research, economic evaluation and policy research, adds strategic consulting in pricing and reimbursement to its array of existing services.

PharmAnalysis Group, Inc. is the most recent acquisition of United BioSource Corp., which also acquired MEDTAP in January 2004. “We are pleased to have PharmAnalysis join us, as part of the MEDTAP team,” said Nancy Kline Leidy, Ph.D., President & CEO of MEDTAP. “Their staff share MEDTAP’s values of excellence and commitment to client service. The addition of highly qualified experts in pricing and reimbursement strengthens MEDTAP’s ability to serve the growing and diverse needs of our clients and promotes our longer-term goal of providing comprehensive health economic and outcomes research and strategic consultation services to our clients.”

PharmAnalysis Group, Inc. assists the pharmaceutical, biotechnology, and medical device industries with complex reimbursement issues. These services span the entire product lifecycle, from pre-launch to post-launch phases, to support client’s marketing and sales goals. “We work as partners with our clients to achieve global payer, provider and patient access for life-altering products. We have been successful in seeing our clients’ products gain market access and, as a result, they choose us to assist them again and again,” says Diane Simison, former President of PharmAnalysis. “Joining forces with MEDTAP is very exciting for us,” says Laurie Hughes, former CEO of PharmAnalysis. “There are many synergies that exist in the offerings of the two companies, so the ability to provide a full range of services to our clients is very appealing and directly responds to our clients’ needs.”

PharmAnalysis will continue to operate out of its Arlington, Virginia headquarters under the leadership of Diane L. Simison, Ph.D. and Laurie G. Hughes, MBA, who will serve as Executive Directors of the new Center for Pricing and Reimbursement. With this addition, MEDTAP offers an even more extensive array of integrated services, including health outcomes, health economics, and now pricing and reimbursement planning.
Edgemont Capital Partners served as exclusive adviser to PharmAnalysis Group.

About MEDTAP International, Inc.
MEDTAP® International, Inc. is a global health services research firm that develops and evaluates patient reported outcomes measures, conducts patient preference studies, performs economic evaluation and modeling studies, and conducts policy research and analysis for pharmaceutical companies, managed care organizations, biotechnology firms, medical device and diagnostics manufacturers, governments and professional and trade associations.
At the heart of MEDTAP is its international team of accomplished scientists, economists, clinicians, academicians and business professionals. Founded in 1984, MEDTAP is one of the world’s original organizations which helped define and develop the field of health economics and outcomes research. Today it is the world’s largest firm solely dedicated to this dynamic field. MEDTAP is headquartered in Bethesda, Maryland, has offices in London and throughout the United States and Europe. For more information about MEDTAP, visit www.MEDTAP.com.

About PharmAnalysis Group, Inc.
PharmAnalysis provides research and market-driven solutions in strategic reimbursement planning for the pharmaceutical, biotechnology, medical device and diagnostics industries, offering a broad range of services throughout the product lifecycle, studying each new assignment from a both a global reimbursement and an economic perspective.

About United BioSource Corporation
United BioSource was formed in 2003 to deliver information-based solutions for the pharmaceutical and life sciences industries. For more information about United BioSource Corp., visit www.unitedbiosource.com or call 202-457-1900.

CONTACT:

At Edgemont Capital Partners

Jeff B. Swearingen, Principal
Phone: 212-867-8935 Fax: 212-937-3816